Clinical Trial Update: Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating transdermal or oral telapristone acetate in patients undergoing mastectomy; trial completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Breast Carcinoma in Situ
• Lobular Breast Carcinoma in Situ
• Stage Ia Breast Cancer
• Stage Ib Breast Cancer
• Stage Iia Breast Cancer
• Stage Iib Breast Cancer

Drugs mentioned

• Telapristone Acetate (telapristone acetate)

Snippet

Sponsor: Northwestern University | Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier | Phase 2 | Status: COMPLETED | Results posted: 2023-02-22